Revive Confirms No Material Undisclosed Information
August 12, 2021 08:12 ET
|
Revive Therapeutics Ltd.
TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
August 10, 2021 07:48 ET
|
Revive Therapeutics Ltd.
Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disordersAdvancing to FDA clinical studies for...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
July 15, 2021 13:31 ET
|
Revive Therapeutics Ltd.
Phase 3 clinical trial ongoing with next DSMB meeting at 600 completed patients.Currently at 41 clinical sites and to engage a minimum of 50 clinical sites.Aim to complete enrollment in Q3-2021 and...
Revive Therapeutics Approved to Trade on the OTCQB Market
June 25, 2021 15:09 ET
|
Revive Therapeutics Ltd.
TORONTO, June 25, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and...
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics
June 17, 2021 08:05 ET
|
Revive Therapeutics Ltd.
TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
June 14, 2021 17:00 ET
|
Revive Therapeutics Ltd.
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
June 08, 2021 08:38 ET
|
Revive Therapeutics Ltd.
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip
May 17, 2021 09:24 ET
|
Revive Therapeutics Ltd.
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19
May 03, 2021 09:15 ET
|
Revive Therapeutics Ltd.
TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury
April 27, 2021 09:17 ET
|
Revive Therapeutics Ltd.
TORONTO, April 27, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...